

Identification of small molecule PKMYT1 inhibitor candidates for development of advanced solid tumor treatment

VORONOI, Inc.



VORONOI

ONCOLOGY	Candidate
Product Type	Small Molecule (kinase inhibitor)
Indication	Refractory Solid tumor with specific biomarkers, such as CCNE1
Target	PKMYT1
MoA(Mechanism of Action)	Induce abnormal cell cycle progression & cancer cell apoptosis through unscheduled activation of CDK1 (premature mitotic entry) in CCNE1-amplified solid tumors.
Competitiveness	<p>RP-6306 : PKMYT1 inhibitor, Phase I/II, Repare Therapeutics</p> <p>ZN-c3 : Wee1 inhibitor, Phase I, Zentalis</p> <p>Debio0123 : Wee1 inhibitor, Phase I, Debiopharm</p> <p>VRN16 is a drug with low off-target liability and is expected to be developed as a drug with a higher safety margin.</p>
Development Stage	Candidate
Route of Administration	Oral